Swedbank AB Decreases Stock Holdings in Illumina, Inc. $ILMN

Swedbank AB lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 96.8% during the 1st quarter, HoldingsChannel reports. The firm owned 26,342 shares of the life sciences company’s stock after selling 799,844 shares during the period. Swedbank AB’s holdings in Illumina were worth $3,247,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in shares of Illumina by 97.0% during the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after buying an additional 1,352,731 shares during the period. AQR Capital Management LLC grew its holdings in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after acquiring an additional 1,028,099 shares during the period. Morgan Stanley increased its position in Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after acquiring an additional 1,005,474 shares during the last quarter. Nordea Investment Management AB increased its position in Illumina by 2,792.2% during the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after acquiring an additional 911,843 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. bought a new position in Illumina in the first quarter valued at about $106,462,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CAO Scott D. Ericksen sold 500 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the transaction, the chief accounting officer owned 14,446 shares of the company’s stock, valued at $2,311,360. This represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the sale, the insider owned 20,953 shares of the company’s stock, valued at $3,771,540. This represents a 2.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Performance

Illumina stock traded down $3.56 during midday trading on Friday, hitting $190.20. The stock had a trading volume of 1,075,437 shares, compared to its average volume of 1,932,858. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $196.66. The company has a market capitalization of $28.78 billion, a PE ratio of 34.58, a P/E/G ratio of 3.56 and a beta of 1.47. The firm’s fifty day moving average is $161.31 and its two-hundred day moving average is $141.50. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.21 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on ILMN shares. Piper Sandler raised their target price on Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Citigroup raised their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Finally, Guggenheim increased their price target on shares of Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $150.44.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina is being highlighted by market commentary as a biotech and life sciences momentum name, with analysts pointing to stronger earnings trends and sector leadership in healthcare. Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
• Positive Sentiment: Several articles frame ILMN as a strong momentum stock and note that it has outperformed recently, reinforcing bullish trading interest. Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know
• Positive Sentiment: Illumina announced new executive appointments, naming Michael Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, which may be viewed as a move to strengthen commercial execution and governance. Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
• Positive Sentiment: Illumina also announced it will report second-quarter 2026 results on July 30, keeping attention on upcoming fundamentals and guidance. Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
• Neutral Sentiment: Coverage also repeated bullish valuation and “mooning stock” themes, but these were largely commentary pieces rather than new company-specific developments. Illumina Stock Gains 43.7% in 2026: What’s Powering the Rally?
• Negative Sentiment: Short-interest data showed no meaningful bearish positioning change, so it does not currently add fresh downside pressure, though the report itself was unusual and offered little real signal. Illumina (ILMN) Stock May Be 27% Undervalued Following Strong Q1 Results

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.